Piramal Pharma · NSE: PPLPHARMA · BSE: 543635

Q1 FY25 results · Apr–Jun 2024

Piramal Pharma reported revenue from operations of ₹1,951.14 crore (up 11.6% from Q1 FY24) and net loss of ₹88.64 crore for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY25	Q1 FY24	YoY	Q4 FY24	QoQ
Revenue from operations	1,951.14	1,748.85	+11.6%	2,552.36	−23.6%
Other income	19.54	38.31	−49.0%	26.38	−25.9%
Total income	1,970.68	1,787.16	+10.3%	2,578.74	−23.6%
Profit before share of associates & JVs and tax	(67.48)	(121.50)	Loss narrowed	215.44	Turned loss
Share of profit/(loss) of associates & JVs	22.40	14.39		12.04
Net profit for the period	(88.64)	(98.58)	Loss narrowed	101.27	Turned loss
EPS, basic (₹)	(0.67)	(0.83)	not comparable	0.77	Turned loss
Net margin (%)	-4.5	-5.6		4.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY25	Q1 FY24	YoY	Q4 FY24	QoQ
Revenue from operations	1,063.20	846.43	+25.6%	1,525.30	−30.3%
Other income	36.76	26.68	+37.8%	53.19	−30.9%
Total income	1,099.96	873.11	+26.0%	1,578.49	−30.3%
Profit before tax	111.66	(40.90)	Turned profit	362.67	−69.2%
Net profit for the period	85.27	(33.36)	Turned profit	273.08	−68.8%
EPS, basic (₹)	0.64	(0.28)	not comparable	2.06	−68.9%
Net margin (%)	8.0	-3.9		17.9

Consolidated

Filed with BSE: 29 Jul 2024, 15:44 IST
Board meeting: 26 Jul 2024
Period: 01 Apr 2024 to 30 Jun 2024
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 29 Jul 2024, 15:44 IST
Board meeting: 26 Jul 2024
Period: 01 Apr 2024 to 30 Jun 2024
Review status: Unaudited
Source: XBRL filing on BSE